KOMIPHARM INTERNATIONAL CO., LTD.
Biopharmaceutical company developing products for animal and human health.
041960 | KO
Overview
Corporate Details
- ISIN(s):
- KR7041960006
- LEI:
- Country:
- South Korea
- Address:
- 경기도 시흥시 경제로 17, 시흥시
- Website:
- https://komipharm.co.kr/en/
- Sector:
- Manufacturing
Description
Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-08-13 00:00 |
반기보고서 (2020.06)
|
Korean | 1.5 MB | ||
| 2020-07-13 00:00 |
투자판단관련주요경영사항(코로나-19 바이러스로 인한 폐렴환자에서 PAX-1의 안전성 및 유효성 평가를 위한 스페인의약품위생제품청(AEMPS) …
|
Korean | 14.6 KB | ||
| 2020-06-25 00:00 |
투자판단관련주요경영사항(코로나-19 바이러스로 인한 폐렴환자에서 PAX-1의 안전성 유효성 평가를 위한 이탈리아의약품청(AIFA) 임상2/3상…
|
Korean | 13.4 KB | ||
| 2020-06-19 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2020-06-08 00:00 |
투자판단관련주요경영사항(파나픽스(Panaphix)의 국내 식약처 긴급임상시험계획 반려)
|
Korean | 9.5 KB | ||
| 2020-06-08 00:00 |
투자판단관련주요경영사항(신종코로나바이러스로 인한 폐렴환자에서 PAX-1의 안전성 유효성 평가를 위한 미국FDA 코로나바이러스치료 가속프로그램(…
|
Korean | 15.2 KB | ||
| 2020-05-29 00:00 |
[기재정정]금전대여결정
|
Korean | 23.5 KB | ||
| 2020-05-14 00:00 |
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 37.5 KB | ||
| 2020-05-14 00:00 |
[기재정정]주식등의대량보유상황보고서(일반)
|
Korean | 228.2 KB | ||
| 2020-05-14 00:00 |
[기재정정]주식등의대량보유상황보고서(일반)
|
Korean | 145.7 KB | ||
| 2020-05-14 00:00 |
분기보고서 (2020.03)
|
Korean | 1.7 MB | ||
| 2020-05-14 00:00 |
투자판단관련주요경영사항(비소세포폐암(NSCLC)에서 이차적으로 뇌전이(BM)가 있는 환자에서의 PAX-1 2상 임상시험계획 승인비소세포폐암(N…
|
Korean | 12.7 KB | ||
| 2020-04-20 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2020-03-31 00:00 |
[기재정정]단일판매ㆍ공급계약체결
|
Korean | 16.1 KB | ||
| 2020-03-30 00:00 |
사업보고서 (2019.12)
|
Korean | 596.2 KB |
Automate Your Workflow. Get a real-time feed of all KOMIPHARM INTERNATIONAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for KOMIPHARM INTERNATIONAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for KOMIPHARM INTERNATIONAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
